Europe's Agrifood Biotech Boom at Risk: What the Netherlands Must Fix

Jan de Vries · 2026-10-30

The Netherlands has long been the quiet overachiever of European agriculture. Tiny country, massive output. But a new report from Invest-NL, the Dutch national investment institution, suggests that crown is starting to slip. And the reasons why matter far beyond Dutch borders—especially if you're watching European startup incorporation trends. ### The Innovation Paradox Here's the frustrating part: the Netherlands doesn't have an innovation problem. It has a scale-up problem. The country produces 3.3% of global biotech startups, yet only 1.3% of scale-ups, according to data from TNO. In plain English? Great ideas, but too few grow into big, globally competitive companies. Invest-NL's report, *Deep Dive Agrifood Biotech*, is based on conversations with over 150 entrepreneurs, investors, researchers, and policymakers. It zeroes in on three areas: seed breeding and genetics, biological agricultural inputs, and biotech-derived food ingredients. The potential is staggering—an estimated $18.5 billion in additional annual revenue by 2040 if the barriers are addressed. But without coordinated action, that opportunity will likely be captured elsewhere. ### Three Problems Holding Companies Back The report identifies three recurring weaknesses: - Too few promising technologies become scalable ventures - Regulatory and validation processes delay market entry - Insufficient financing prevents companies from reaching industrial production These aren't abstract policy issues. They're the daily reality for founders trying to build the next generation of agrifood companies in Europe. ### The "Ten Years to Say Yes" Problem Perhaps the most striking finding concerns biological crop protection. Dutch companies are developing alternatives to conventional chemical pesticides—a market that could expand seven- to tenfold by 2040. But getting European regulatory approval can take eight to ten years. Existing frameworks were designed around chemical products, making them a poor fit for biological innovations. So what happens? Companies launch in Brazil and the United States instead, where commercialization moves faster. Europe risks losing ground in a market it helped create. Food biotechnology faces similar hurdles. Regulatory approval for novel ingredients takes one to three years longer in Europe than in the U.S., while building a first commercial production facility can require tens or even hundreds of millions of dollars. For fermentation-derived food ingredients alone, Invest-NL estimates that favorable conditions could support around $8.7 billion in annual Dutch revenues by 2040—compared with just $2.2 billion under current policies. As the report puts it: "Innovation is not the issue. Commercialization is." ### What Needs to Change The report stresses that faster approvals shouldn't come at the expense of safety. Instead, regulators should offer earlier guidance, more predictable assessments, and opportunities for companies to validate products under real-world conditions. Crucially, the Netherlands doesn't need to manufacture everything domestically. It should focus on retaining strategically valuable knowledge, intellectual property, companies, and specialized capabilities—while tapping into European production networks where it makes sense. ### The Bigger Picture for European Startups For anyone following EU Inc news and European startup incorporation, this report is a wake-up call. The barriers facing Dutch agrifood biotech companies are the same ones facing founders across Europe. Regulatory delays, financing gaps, and the difficulty of scaling from startup to industrial production are not uniquely Dutch problems—they're European ones. If Europe wants to keep its best agrifood innovations at home, it needs to move faster. The Netherlands has a strong start, but a weaker finish. The question is whether that's a warning or a blueprint for the rest of the continent.